Feasibility of rTMS combined with dexmedetomidine in chronic insomnia disorder
7.0
来源：
Nature
关键字：
ML brain science
发布时间：
2025-09-30 03:35
摘要：
The study investigates the combined use of repetitive transcranial magnetic stimulation (rTMS) and dexmedetomidine (DEX) for chronic insomnia disorder. Results indicate significant improvements in sleep quality, with reductions in anxiety and depression symptoms lasting for six months. The combination therapy enhanced deep sleep and REM sleep while decreasing light sleep and awakenings. The findings suggest a promising approach to treating chronic insomnia, addressing both sleep quality and associated mood disorders.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
0.5
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.0
关键证据
Significant decrease in PSQI, HAMA, and HAMD scores post-treatment.
Improvement in sleep structure with increased deep sleep and REM sleep.
Combination treatment showed lasting effects for up to 6 months.
真实性检查
否
AI评分总结
The study investigates the combined use of repetitive transcranial magnetic stimulation (rTMS) and dexmedetomidine (DEX) for chronic insomnia disorder. Results indicate significant improvements in sleep quality, with reductions in anxiety and depression symptoms lasting for six months. The combination therapy enhanced deep sleep and REM sleep while decreasing light sleep and awakenings. The findings suggest a promising approach to treating chronic insomnia, addressing both sleep quality and associated mood disorders.